JP2009106299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009106299A5 JP2009106299A5 JP2008314107A JP2008314107A JP2009106299A5 JP 2009106299 A5 JP2009106299 A5 JP 2009106299A5 JP 2008314107 A JP2008314107 A JP 2008314107A JP 2008314107 A JP2008314107 A JP 2008314107A JP 2009106299 A5 JP2009106299 A5 JP 2009106299A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- nkg2
- cells
- cell
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 42
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims 33
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims 33
- 238000000034 method Methods 0.000 claims 33
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 29
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 claims 26
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 25
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims 23
- 102000005962 receptors Human genes 0.000 claims 9
- 108020003175 receptors Proteins 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 101150069255 KLRC1 gene Proteins 0.000 claims 3
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims 3
- 210000000822 natural killer cell Anatomy 0.000 claims 3
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 2
- 108091008877 NK cell receptors Proteins 0.000 claims 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000000415 inactivating effect Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 108090001008 Avidin Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9725764.6A GB9725764D0 (en) | 1997-12-04 | 1997-12-04 | HLA-E binding |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000523554A Division JP4336451B2 (ja) | 1997-12-04 | 1998-12-04 | Ｈｌａ−ｅ結合 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009191564A Division JP5268828B2 (ja) | 1997-12-04 | 2009-08-21 | Ｈｌａ−ｅ結合 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009106299A JP2009106299A (ja) | 2009-05-21 |
| JP2009106299A5 true JP2009106299A5 (cg-RX-API-DMAC10.html) | 2009-07-02 |
| JP4437160B2 JP4437160B2 (ja) | 2010-03-24 |
Family
ID=10823165
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000523554A Expired - Lifetime JP4336451B2 (ja) | 1997-12-04 | 1998-12-04 | Ｈｌａ−ｅ結合 |
| JP2008314107A Expired - Lifetime JP4437160B2 (ja) | 1997-12-04 | 2008-12-10 | Ｈｌａ−ｅ結合 |
| JP2009191564A Expired - Lifetime JP5268828B2 (ja) | 1997-12-04 | 2009-08-21 | Ｈｌａ−ｅ結合 |
| JP2013006244A Abandoned JP2013081478A (ja) | 1997-12-04 | 2013-01-17 | Ｈｌａ−ｅ結合 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000523554A Expired - Lifetime JP4336451B2 (ja) | 1997-12-04 | 1998-12-04 | Ｈｌａ−ｅ結合 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009191564A Expired - Lifetime JP5268828B2 (ja) | 1997-12-04 | 2009-08-21 | Ｈｌａ−ｅ結合 |
| JP2013006244A Abandoned JP2013081478A (ja) | 1997-12-04 | 2013-01-17 | Ｈｌａ−ｅ結合 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7410767B1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP1036327B1 (cg-RX-API-DMAC10.html) |
| JP (4) | JP4336451B2 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE438096T1 (cg-RX-API-DMAC10.html) |
| DE (1) | DE69841020D1 (cg-RX-API-DMAC10.html) |
| GB (1) | GB9725764D0 (cg-RX-API-DMAC10.html) |
| WO (1) | WO1999028748A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9725764D0 (en) * | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| EP1423140A2 (en) * | 2001-07-31 | 2004-06-02 | Karl Petter Söderström | Compositions and methods for modulation of immune responses |
| US20040072262A1 (en) | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
| CA2541241A1 (en) * | 2003-08-26 | 2005-03-03 | Danmarks Tekniske Universitet | A continuous process for the assembly of macromolecular substances and the subsequent capture and isolation of a macromolecular assembly, and a system suitable for the process |
| EP1766393A4 (en) * | 2004-05-07 | 2008-06-18 | Beckman Coulter Inc | MHC-BRIDGE SYSTEM FOR DETECTION OF THE CTL-MEDIATED LYSE OF ANTIGEN-PRESENTING CELLS |
| EP2226332A1 (en) | 2004-06-17 | 2010-09-08 | Beckman Coulter, Inc. | Mycobacterium tuberculosis epitopes and methods of use thereof |
| RU2481356C2 (ru) | 2004-12-28 | 2013-05-10 | Иннейт Фарма | Моноклональные антитела против nkg2a |
| US7932055B2 (en) * | 2006-06-22 | 2011-04-26 | Novo Nordisk A/S | Soluble heterodimeric CD94/NKG2 receptors fusion proteins |
| DK2038306T3 (en) | 2006-06-30 | 2015-03-09 | Novo Nordisk As | ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF |
| MX2010007935A (es) | 2008-01-24 | 2010-08-23 | Novo Nordisk As | Anticuerpo monoclonal humanizado anti-nkg2a humano. |
| MX342131B (es) | 2011-06-17 | 2016-09-14 | Novo Nordisk As | Eliminacion selectiva de celulas erosivas. |
| US11471486B2 (en) | 2012-09-04 | 2022-10-18 | Inven2 As | Selective and controlled expansion of educated NK cells |
| US20150037304A1 (en) * | 2013-03-12 | 2015-02-05 | Sangamo Biosciences, Inc. | Methods and compositions for modification of hla |
| ES2769574T3 (es) | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| WO2015142661A1 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| WO2015148960A1 (en) * | 2014-03-28 | 2015-10-01 | The Board Of Regents Of The University Of Oklahoma | Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| KR20250007689A (ko) | 2014-09-16 | 2025-01-14 | 이나뜨 파르마 에스.에이. | 림프구에서의 억제 경로의 중화 |
| AU2015316993B2 (en) | 2014-09-16 | 2021-03-18 | Innate Pharma | Treatment regimens using anti-NKG2A antibodies |
| US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| EP3209687A1 (en) | 2014-10-23 | 2017-08-30 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| SMT202100280T1 (it) | 2016-01-21 | 2021-07-12 | Innate Pharma | Neutralizzazione delle vie inibitorie nei linfociti |
| EP3573997A4 (en) * | 2017-01-24 | 2020-12-09 | Abexxa Biologics, Inc. | METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| CN112351795A (zh) * | 2018-02-23 | 2021-02-09 | 安贝科思生物制剂公司 | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 |
| US11464840B2 (en) | 2018-02-26 | 2022-10-11 | Swey-Shen Chen | Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers |
| TWI924623B (zh) | 2018-03-13 | 2026-05-11 | 法商天賜製藥公司 | 頭頸癌之治療 |
| EP3539552A1 (en) * | 2018-03-16 | 2019-09-18 | Deutsches Rheuma-Forschungszentrum Berlin | Activation and expansion of nkg2c+ nk cells |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| MX2021005708A (es) | 2018-11-16 | 2021-09-21 | Bristol Myers Squibb Co | Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos. |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| JP2022510207A (ja) * | 2018-12-02 | 2022-01-26 | フェイト セラピューティクス，インコーポレイテッド | 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| GB201909509D0 (en) * | 2019-07-02 | 2019-08-14 | Immunocore Ltd | Peptide-MHC complexes |
| EP4221752A4 (en) | 2020-09-30 | 2024-12-04 | Dren Bio, Inc. | ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF |
| CA3229447A1 (en) * | 2021-08-20 | 2023-02-23 | Duke University | Antibodies that target hla-e-host peptide complexes and uses thereof |
| EP4569117A2 (en) * | 2022-08-11 | 2025-06-18 | The Trustees of The University of Pennsylvania | Universal t cells and compositions and methods of use thereof |
| EP4688859A1 (en) * | 2023-03-24 | 2026-02-11 | Duke University | Antibodies that target hla-e-host peptide complexes and uses thereof |
| WO2026016730A1 (zh) * | 2024-07-17 | 2026-01-22 | 广州瑞风生物科技股份有限公司 | 一种突变hla-e重链、hla-e三聚体及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03112487A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞 |
| JPH03112486A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞 |
| JPH03112485A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞 |
| GB9725764D0 (en) * | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
-
1997
- 1997-12-04 GB GBGB9725764.6A patent/GB9725764D0/en not_active Ceased
-
1998
- 1998-12-04 AT AT98959027T patent/ATE438096T1/de not_active IP Right Cessation
- 1998-12-04 US US09/555,555 patent/US7410767B1/en not_active Expired - Fee Related
- 1998-12-04 EP EP98959027A patent/EP1036327B1/en not_active Expired - Lifetime
- 1998-12-04 WO PCT/GB1998/003686 patent/WO1999028748A2/en not_active Ceased
- 1998-12-04 EP EP09165917A patent/EP2144065A1/en not_active Withdrawn
- 1998-12-04 DE DE69841020T patent/DE69841020D1/de not_active Expired - Lifetime
- 1998-12-04 JP JP2000523554A patent/JP4336451B2/ja not_active Expired - Lifetime
-
2008
- 2008-04-25 US US12/109,990 patent/US20080274475A1/en not_active Abandoned
- 2008-12-10 JP JP2008314107A patent/JP4437160B2/ja not_active Expired - Lifetime
-
2009
- 2009-08-21 JP JP2009191564A patent/JP5268828B2/ja not_active Expired - Lifetime
-
2013
- 2013-01-17 JP JP2013006244A patent/JP2013081478A/ja not_active Abandoned
-
2015
- 2015-04-10 US US14/683,835 patent/US20150361180A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002513541A5 (cg-RX-API-DMAC10.html) | ||
| US20200208114A1 (en) | Taxonomy and use of bone marrow stromal cell | |
| Okholm et al. | Quantification of cellular uptake of DNA nanostructures by qPCR | |
| Moussu et al. | ZHOUPI and KERBEROS mediate embryo/endosperm separation by promoting the formation of an extracuticular sheath at the embryo surface | |
| CN103205431B (zh) | 一种核酸适配体及其衍生物、核酸适配体的筛选方法及在检测人胆管癌细胞株中的应用 | |
| Gao et al. | Human Tudor staphylococcal nuclease (Tudor-SN) protein modulates the kinetics of AGTR1-3′ UTR granule formation | |
| CN110117595B (zh) | 一种特异性结合pdl1的核酸适配体及其应用 | |
| US10471057B2 (en) | Toxic RNA inhibitors self-assembled in situ | |
| US20180327827A1 (en) | Method of isolating nucleic acid | |
| JP2008502332A5 (cg-RX-API-DMAC10.html) | ||
| CN102449476A (zh) | 筛选抑制目标蛋白质-蛋白质相互作用的候选新药以开发一类药物的方法 | |
| JP5349838B2 (ja) | ｓｍａｌｌＲＮＡの取得用担体、取得方法及び取得用試薬 | |
| Brouwer et al. | Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients | |
| US11708605B2 (en) | Synthetic strands for nucleic acid sequencing and related methods and systems | |
| Lee et al. | Chimeric peptide-based biomolecular constructs for versatile nucleic acid biosensing | |
| KR101513766B1 (ko) | 알파태아단백질에 특이적으로 결합하는 ｄｎａ 앱타머 및 이의 용도 | |
| CN112126649B (zh) | 基于工程化细胞的N-cadherin核酸适配体的筛选及应用 | |
| KR20180018703A (ko) | 유전자 변형 비-인간 동물 및 보체-의존성 세포 독성에 관한 방법 | |
| Li et al. | Integrated Three-Dimensional Microdevice with a Modified Surface for Enhanced DNA Separation from Biological Samples | |
| JP5965398B2 (ja) | 任意の種類の注目される核酸配列に結合するタンパク質を単離するための新規な方法 | |
| EP2773769A1 (en) | Methods relating to identification of susceptibilty to liver injury | |
| US10526608B2 (en) | In vitro selection of formaldehyde cross-linking aptamers | |
| EP4737896A1 (en) | Method for spatial analysis of genetically-modified cell therapy products in situ | |
| US9890418B1 (en) | Method of detecting nucleic acids with enhanced signal using dual-functional capture particles | |
| EP2985290B1 (en) | Depletion of mouse cells for isolation of human cells |